Relation of Bone Mineral Density with Homocysteine and Cathepsin K levels in Postmenopausal Women

Madhukar Mittal, Rajeev Verma, Arvind Mishra, Ajay Singh, Vivek Kumar, K K Sawlani, M Kaleem Ahmad, Pratishtha Mishra, Rishika Gaur, Madhukar Mittal, Rajeev Verma, Arvind Mishra, Ajay Singh, Vivek Kumar, K K Sawlani, M Kaleem Ahmad, Pratishtha Mishra, Rishika Gaur

Abstract

Background: Homocysteine (HCY) interferes with collagen cross-linking in bones and stimulates osteoclast activity. The activated osteoclasts secrete cathepsin K (CathK), a cysteine protease, in eminent quantity during bone resorption. Hyperhomocysteinemia may effect bone mineral density (BMD) through CathK. We, therefore, examined the relation between HCY and BMD along with CathK, 25-hydroxyvit-D (25[OH]D), intact parathyroid hormone (iPTH), and Vitamin B12.

Materials and methods: We recruited a total of 93 postmenopausal women between the age group of 45-60 years, attending the Endocrinology outpatient department at King George's Medical University, Lucknow. BMD was done by DXA scan using Hologic QDR1000 system. Based on the WHO criteria, patients were segregated into three groups as follows; normal bone mass, osteopenia, and osteoporosis. All women underwent routine biochemical laboratory parameters, HCY, Vitamin B12, and CathK levels.

Results: Among 93 postmenopausal women, 56% (52) had osteoporosis. Nineteen percent (18) had normal BMD (mean age, 53.22 ± 8.5 years) and 23 (25%) had osteopenia (mean age 52.86 ± 6.67 years). The mean age in the osteoporetic group was 56.2 ± 6.9 years. The median (interquartile range) levels of HCY in the three groups were 14.5 μmol/L (12.2-24.7), 15.05 μmol/L (12.1-19.9) and 13.2 μmol/L (10.3-17.0), respectively. CathK levels were similar in three groups 7.6 ng/ml (7.0-80.5), 8.3 ng/ml (7.3-8.5), and 8.6 ng/ml (7.2-8.9). Both HCY and CathK were found positively associated with serum phosphorus (r = 0.584, P < 2.01 and r = 0.249, P < 0.05, respectively). Levels of HCY positively correlate with PTH (r = 0.303, P < 0.01) and inversely with Vitamin B12 (r = -0.248, P < 0.05). No significant association was seen between CathK level and 25(OH) D, iPTH, serum calcium.

Conclusion: Low bone mass by DXA is a significant problem in postmenopausal females. HCY and CathK do not reliably correlate with bone loss in postmenopausal women although phosphorus metabolism may play a role.

Keywords: Bone mineral density; cathepsin K; homocysteine; osteoporosis; postmenopausal.

Conflict of interest statement

There are no conflicts of interest.

References

    1. Tuck SP, Datta HK. Osteoporosis in the aging male: Treatment options. Clin Interv Aging. 2007;2:521–36.
    1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA. 1999;282:1344–52.
    1. Bahtiri E, Islami H, Rexhepi S, Qorraj-Bytyqi H, Thaçi K, Thaçi S, et al. Relationship of homocysteine levels with lumbar spine and femur neck BMD in postmenopausal women. Acta Reumatol Port. 2015;40:355–62.
    1. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res. 2007;22:127–34.
    1. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klift M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004;350:2033–41.
    1. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Meyer HE, Tell GS, et al. Plasma homocysteine, folate, and Vitamin B 12 and the risk of hip fracture: The hordaland homocysteine study. J Bone Miner Res. 2007;22:747–56.
    1. Kim JI, Moon JH, Chung HW, Kong MH, Kim HJ. Association between homocysteine and bone mineral density according to age and sex in healthy adults. J Bone Metab. 2016;23:129–34.
    1. Green TJ, McMahon JA, Skeaff CM, Williams SM, Whiting SJ. Lowering homocysteine with B Vitamins has no effect on biomarkers of bone turnover in older persons: A 2-y randomized controlled trial. Am J Clin Nutr. 2007;85:460–4.
    1. Vacek TP, Kalani A, Voor MJ, Tyagi SC, Tyagi N. The role of homocysteine in bone remodeling. Clin Chem Lab Med. 2013;51:579–90.
    1. Fratoni V, Brandi ML. B Vitamins, homocysteine and bone health. Nutrients. 2015;7:2176–92.
    1. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for mcKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta. 1996;1315:159–62.
    1. Jahn O, Wex T, Klose S, Kropf S, Adolf D, Piatek S, et al. Cathepsin K in treatment monitoring following intravenous zoledronic acid. Biomed Rep. 2014;2:915–7.
    1. Holzer G, Noske H, Lang T, Holzer L, Willinger U. Soluble cathepsin K: A novel marker for the prediction of nontraumatic fractures? J Lab Clin Med. 2005;146:13–7.
    1. Muñoz-Torres M, Reyes-García R, Mezquita-Raya P, Fernández-García D, Alonso G, Luna Jde D, et al. Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate. Maturitas. 2009;64:188–92.
    1. Borker SA, Venugopalan PP, Bhat SN. Study of menopausal symptoms, and perceptions about menopause among women at a rural community in Kerala. J Midlife Health. 2013;4:182–7.
    1. Lu Y, Genant HK, Shepherd J, Zhao S, Mathur A, Fuerst TP, et al. Classification of osteoporosis based on bone mineral densities. J Bone Miner Res. 2001;16:901–10.
    1. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W, et al. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem. 2005;51:2348–53.
    1. Cagnacci A, Bagni B, Zini A, Cannoletta M, Generali M, Volpe A, et al. Relation of folates, Vitamin B12 and homocysteine to vertebral bone mineral density change in postmenopausal women. A five-year longitudinal evaluation. Bone. 2008;42:314–20.
    1. Zhang H, Tao X, Wu J. Association of homocysteine, Vitamin B12, and folate with bone mineral density in postmenopausal women: A meta-analysis. Arch Gynecol Obstet. 2014;289:1003–9.
    1. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, folate, and Vitamin B12 to bone mineral density of postmenopausal women. Bone. 2003;33:956–9.
    1. Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res. 2005;20:152–158.
    1. Kumar J, Garg G, Kumar A, Sundaramoorthy E, Sanapala KR, Ghosh S, et al. Single nucleotide polymorphisms in homocysteine metabolism pathway genes: Association of CHDH A119C and MTHFR C677T With hyperhomocysteinemia. Circ Cardiovasc Genet. 2009;2:599–606.
    1. Meier C, Meinhardt U, Greenfield JR, De Winter J, Nguyen TV, Dunstan CR, et al. Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with paget's disease. Clin Lab. 2006;52:1–0.
    1. Adolf D, Wex T, Jahn O, Riebau C, Halangk W, Klose S, et al. Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women. Maturitas. 2012;71:169–72.
    1. Garnero P. New biochemical markers of bone turnover. IBMS BoneKEy. 2008;5:84–102.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner